Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1524512 | 0.91 | SMN1; SMN2 (0.65) | SMN1; SMN2MEN1RAB9AKMT2AMAOB | |
| SCHEMBL7848337 | 0.87 | SMN1; SMN2 (0.69) | SMN1; SMN2MEN1RAB9AKMT2AMAOB | |
| SCHEMBL4815387 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2MEN1RAB9AKMT2AMAOB | |
| SCHEMBL5274392 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2MEN1RAB9AKMT2AMAOB | |
| SCHEMBL12412550 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2MEN1RAB9AKMT2APOLB | |
| SCHEMBL12655102 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2MEN1RAB9AKMT2AMAOB | |
| SCHEMBL8219820 | 0.83 | SMN1; SMN2 (0.73) | SMN1; SMN2MEN1RAB9AKMT2AMAOB | |
| SCHEMBL1283871 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2MEN1RAB9AKMT2ANR4A2 | |
| SCHEMBL28985501 | 0.83 | SMN1; SMN2 (0.63) | SMN1; SMN2MEN1RAB9AKMT2AMAOB | |
| SCHEMBL1396854 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2MEN1RAB9AKMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874792-B1 | ACTIVATORS FOR OLIGONUCLEOTIDE AND PHOSPHORAMIDITE SYNTHESIS | SIGMA ALDRICH CO LLC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-8138330-B2 | Solid phase synthesis via deblocking immobilized nucleoside, then coupling acyl protected nucleoside phosphoramidite | SIGMA-ALDRICH CO. LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-7897758-B2 | Activators for oligonucleotide and phosphoramidite synthesis | SIGMA-ALDRICH CO. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090137790-A1 | METHOD OF CAPPING OLIGONUCLEIC ACID | NIPPON SHINYAKU CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2017282-A1 | METHOD OF CAPPING OLIGONUCLEIC ACID | Nippon Shinyaku Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | SIGMA ALDRICH COMPANY (US) | 2008-03-13 | — | — | US | disclosed |
| EP-1874792-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE AND PHOSPHORAMIDITE SYNTHESIS | Sigma Aldrich Company (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20060247431-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE AND PHOSPHORAMIDITE SYNTHESIS | SIGMA-ALDRICH CO. (US) | 2006-11-02 | — | — | US | disclosed |
| WO-2006116476-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE AND PHOSPHORAMIDITE SYNTHESIS | SIGMA-ALDRICH CO. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064867-A1 | PROCESS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES | RNGTT, DUT, ADAR | SMN1; SMN2 1394/4885MEN1 4441/4885RAB9A 4469/4885 |
| US-20090137790-A1 | METHOD OF CAPPING OLIGONUCLEIC ACID | RNGTT, DUT, ADAR | SMN1; SMN2 2506/4885MEN1 3961/4885RAB9A 4438/4885 |
| US-20060247431-A1 | ACTIVATORS FOR OLIGONUCLEOTIDE AND PHOSPHORAMIDITE SYNTHESIS | PFAS, NUDT1, PNP | SMN1; SMN2 3061/4885MEN1 4469/4885RAB9A 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.